The information on this website is intended for healthcare professionals only and is provided solely for the purpose of scientific exchange. By accessing this website you accept this legal disclaimer and you expressly confirm your status as a healthcare professional.
This website is not country specific and may therefore contain information that is not applicable to your country. The website is not intended to provide medical advice and/or treatment guidance. Therefore, before prescribing any product, always refer to information approved by regulatory authorities in your country such as the prescribing information and/or the Summary of Product Characteristics. Novo Nordisk accepts no liability for the accuracy, completeness or use of information on this website, and disclaims any liability to update the information contained on this website.
Dr Sue D. Pedersen is a certified American Board of Obesity Medicine diplomate and specialist in endocrinology and metabolism. She has a busy endocrinology practice at the C-endo Diabetes and Endocrinology Clinic in Calgary, AB, Canada, with a focus on obesity and type 2 diabetes.
Dr Pedersen completed her training as an endocrinologist at the University of Calgary, AB, Canada in 2005. She has worked at the Royal University Hospital, SK, Canada, and held a research sabbatical at the University of Copenhagen, Denmark. She serves as a principal and/or national investigator and co-author of several research studies, including studies of pharmacotherapy for obesity and for diabetes.
Dr Pedersen has a prominent role with Obesity Canada. She is the lead author of the chapter ‘Pharmacotherapy in Obesity Management’ in the 2020 Canadian Adult Obesity Clinical Practice Guidelines. She is also a member of the expert committee for the 2018 Diabetes Canada guidelines as an author on the chapter ‘Weight Management in Diabetes’. Dr Pedersen maintains a public information website about weight management and diabetes at www.drsue.ca.